
Opinion|Videos|April 11, 2025
Managing Safety and Quality of Life With Cemiplimab in Advanced NSCLC
Author(s)Eric K. Singhi, M.D., Ben Creelan, M.D.
Panelists discuss how balancing survival benefits with quality of life involves careful monitoring of treatment-related adverse effects. Managing immune-related adverse events in patients on immune checkpoint inhibitors like cemiplimab requires early detection, timely intervention and proactive strategies to minimize impact on outcomes.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How are potential survival benefits balanced with impacts on patients’ quality of life, particularly in the context of treatment-related adverse effects?
- How do you approach the management of immune-related adverse events in patients receiving immune checkpoint inhibitors like cemiplimab?
- What proactive strategies do you use to minimize the impact of treatment-related adverse events on patient outcomes?
Advertisement
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Daraxonrasib trial exceeds expectations after decades of disappointment in pancreatic cancer drug development
2
Alyana Samai, M.P.H. | 2026 MHE Emerging Leaders in Healthcare
3
Brukinsa provides long-term disease control in chronic lymphocytic leukemia
4
FDA approves Differin Epiduo Acne Gel for over-the-counter use
5


























